Bio-Rad Laboratories (BIO)
NYSE:BIO
Want to see BIO full AI Analyst Report?
Total Valuation
Bio-Rad Laboratories has a market cap or net worth of $7.72B. The enterprise value is $8.65B.
Market Cap$7.72B
Enterprise Value$8.65B
Share Statistics
Bio-Rad Laboratories has 21,700,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,700,560
Owned by Insiders22.62%
Owned by Institutions23.55%
Financial Efficiency
Bio-Rad Laboratories’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 2.04%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)2.04%
Return on Capital Employed (ROCE)0.03
Revenue Per Employee335.48K
Profits Per Employee98.69K
Employee Count7,700
Asset Turnover0.24
Inventory Turnover1.67
Valuation Ratios
The current PE Ratio of Bio-Rad Laboratories is ―. Bio-Rad Laboratories’s PEG ratio is -0.08.
PE Ratio―
PS Ratio3.20
PB Ratio1.11
Price to Fair Value1.11
Price to FCF22.05
Price to Operating Cash Flow15.20
PEG Ratio-0.08
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.58B and earned 759.90M in profits. Earnings per share was 27.87.
Revenue2.58B
Gross Profit1.34B
Operating Income270.50M
Pretax Income995.50M
Net Income759.90M
EBITDA475.90M
Earnings Per Share (EPS)27.87
Cash Flow
In the last 12 months, operating cash flow was 510.40M and capital expenditures -153.20M, giving a free cash flow of 357.20M billion.
Operating Cash Flow510.40M
Free Cash Flow357.20M
Free Cash Flow per Share16.46
Dividends & Yields
Bio-Rad Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change26.73%
50-Day Moving Average273.21
200-Day Moving Average292.49
Relative Strength Index (RSI)61.66
Average Volume (3m)394.35K
Important Dates
Bio-Rad Laboratories upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Bio-Rad Laboratories as a current ratio of 5.62, with Debt / Equity ratio of 20.12%
Current Ratio5.62
Quick Ratio4.19
Debt to Market Cap0.17
Net Debt to EBITDA2.10
Interest Coverage Ratio5.52
Taxes
In the past 12 months, Bio-Rad Laboratories has paid 235.60M in taxes.
Income Tax235.60M
Effective Tax Rate0.24
Enterprise Valuation
Bio-Rad Laboratories EV to EBITDA ratio is 19.46, with an EV/FCF ratio of 24.72.
EV to Sales3.58
EV to EBITDA19.46
EV to Free Cash Flow24.72
EV to Operating Cash Flow17.40
Balance Sheet
Bio-Rad Laboratories has $1.56B in cash and marketable securities with $1.38B in debt, giving a net cash position of $186.50M billion.
Cash & Marketable Securities$1.56B
Total Debt$1.38B
Net Cash$186.50M
Net Cash Per Share$8.59
Tangible Book Value Per Share$245.74
Margins
Gross margin is 51.87%, with operating margin of 10.47%, and net profit margin of 29.42%.
Gross Margin51.87%
Operating Margin10.47%
Pretax Margin38.54%
Net Profit Margin29.42%
EBITDA Margin18.42%
EBIT Margin10.47%
Analyst Forecast
The average price target for Bio-Rad Laboratories is $296.25, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$296.25
Price Target Upside-0.93% Downside
Analyst ConsensusHold
Analyst Count4
Revenue Growth Forecast1.92%
EPS Growth Forecast―